Two Effective Ways of Protecting Babies from RSV
As the colder months approach, so does the return of respiratory syncytial virus (RSV). Let’s explore some key measures to keep our little ones healthy and safe!
Why is RSV a Concern?
Respiratory syncytial virus (RSV) typically causes mild, cold-like symptoms in older children and adults. Nearly all children under age 2 will contract RSV, with the youngest facing the greatest challenges. About 2-3 out of every 100 young infants require hospitalization, resulting in 58,000 to 80,000 admissions annually. In these infants, the virus can settle in the lungs, leading to bronchiolitis—an inflammation of the small airways that makes breathing difficult. What may seem like a mild illness can escalate quickly.
Understanding the RSV Preventative Antibody Injection
The RSV Preventative Antibody injection, known as Beyfortus (nirsevimab), provides immunity through specially designed antibodies targeting RSV. It offers immediate, “ready-made” protection against the virus, with clinical studies showing an 80% reduction in hospitalization risk.
Beyfortus is generally well tolerated, with uncommon side effects that may include pain, redness, or swelling at the injection site and mild rash. Beyfortus builds on over 25 years of safe use of Synagis, a previous formulation that has been safely administered to millions of high-risk infants. However, Synagis required monthly injections, limiting its use. In contrast, Beyfortus simplifies the process with a single-dose option that provides lasting protection throughout the RSV season and is now available for all young infants.
Who Should Get the Injection?
- All infants under 8 months during their first RSV season (October to March).
- Infants between 8 and 19 months old at high risk, such as those with chronic lung disease or congenital heart disease, during their second RSV season.
An Earlier Opportunity: The RSV Vaccine for Expecting Mothers
Another way to protect your baby is the RSV vaccine for pregnant women, which prompts the mother’s immune system to produce antibodies passed through the placenta. Vaccinating mom at 32-36 weeks (at least 14 days before delivery) provides vital protection during the first months of an infant’s life. It significantly reduces the risk of hospitalization by about 60% and ICU admission by 80% for vaccinated infants.
If you are pregnant, discuss your eligibility with your OB. Babies whose moms received the vaccine typically do not need the RSV Preventative Antibody, as they have protection from maternal antibodies.
Important Supply and Administration Information
Beyfortus can be provided at the birth hospital, but availability may vary, so we encourage you to take advantage of this opportunity to protect your newborn when it arises. The DPH is supplying a limited quantity of the RSV Preventative Antibody injection to pediatric offices, which we will administer on a first-come, first-served basis. This injection can be given alongside routine immunizations during wellness visits or at nurse-only appointments.
For More Information
Navigating infant healthcare can be complex, but staying informed is key. For additional resources, you can visit the following websites:
- CDC RSV Information
- Children's Hospital of Philadelphia Vaccine Education Center
- Healthy Children: RSV Immunizations
Together, we can keep our little ones safe and healthy!
